Pernix and company ink $75M deal to put Orexigen out of its misery
admin 24th April 2018 Uncategorised 0It’s been a painful few years for Orexigen Therapeutics in the obesity arena, and the company is finally ready to bow out. The San-Diego based drugmaker has inked a pact with Nalpropion Pharmaceuticals—a new company funded in part by specialty drugmaker Pernix Therapeutics—to sell worldwide rights to obesity med Contrave and other assets for $75 million in cash.
More: Pernix and company ink M deal to put Orexigen out of its misery
Source: fierce